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1. Introduction 
There have been many attempts to improve absorption and bioavailability of poorly water-
soluble drugs [1-3]. One of attractive systems is microemulsions which are composed of fine 
oil-in-water droplets in aqueous medium [4-8]. When such a formulation is released into the 
lumen of the gut, it disperses to form a fine emulsion, so that the drug remains in liquid 
state in the gut avoiding dissolution step that frequently limits the rate of absorption of 
liphophilic drugs [9]. The smaller sizes of droplets will have a larger interfacial surface areas 
per unit volume and correspondingly large free energy contribution from the liquid-liquid 
interfacial tension [10].  
Self emulsify drug delivery system (SEDDS) is a potency microemulsions for enhancing 
bioavailability of poorly water soluble drugs after oral administration. Microemulsion is a 
system of thermodynamically stable and isotropically clear dispersions of two immiscible 
liquids such as oil and water, stabilized by an interfacial film of surfactant molecules [8,9]. 
Microemulsion formulations are a good candidate for oral delivery of poorly water-soluble 
drugs, because of their ability to improve drug solubilization and potential for enhancing 
absorption in the gastrointestinal tract (GI), caused by surfactant-induced permeability 
changes [11]. After oral administration, it rapidly disperses in stomach forming small 
droplets (<5 μm), which promotes wide distribution of the drug throughout the GI tract. In 
the past decade, we have developed lipophilic drugs microemulsion [6], hydrophobic drug 
emulsion [12], and thermal sensitive microemulsion[13] for enhancing water insoluble drugs 
bioavailability. In this chapter, we discuss on the enhancing bioavailability of the poorly 
water soluble drugs after oral administration by using microemulsion system. Poorly water 
soluble drug has been designed as a thermal reversible microemulsion system, which can 
disperse rapidly in the aqueous contents of the stomach and form fine oil in water droplets, 
and thus leads to improve absorption of the poorly water soluble drugs. 
2. Microemulsion system for oral delivery of lipophilic drugs  
2.1 Preparation of pseudo-ternary phase diagram 
Cyclosporin A as a lipophilic drug model, Caprylic/capric triglyceride (Captex 355) as a oil, 
and Polyoxyethylated castor oil (Cremorphor EL) and Transcutol as a surfactant and 
cosurfactant, respectively, were used for preparation of a series of microemulsions. Surfactant 
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(Cremophor EL) was mixed with cosurfactant (Transcutol) in fixed weight ratios (0.5:1, 1:1, 
2:1 and 4:1). Aliquots of each surfactant-cosurfactant mixture (Smix) were then mixed with oil 
(Captex 355) and finally with aqueous phase (saline or 0.1 N HCl). Mixtures were gently 
shaken or mixed by vortexing and kept at ambient temperature (25C) to equilibrate. The 
equilibrated samples were then assessed visually and determined as being clear and 
transparent microemulsions, or crude emulsions or gels as shown in Figure 1.  
 
Fig. 1. Pseudo-ternary phase diagrams composed of oil (Captex 355), Cremophor EL-
Transcutol mixture (Smix) (Cremophor EL: Transcutol= 4:1) and water. Keys: G, gel; L, 
isotropic region ; ME, single phase o/w microemulsion; E1, crude emulsion; E2, w/o 
emulsion region. 
Phase studies were done to investigate the effect of surfactant/cosurfactant ratio on the 
extent of stable o/w microemulsion region. The microemulsions in the present study were 
formed spontaneously at ambient temperature when their components were brought into 
contact. It is advantageous for developing oral dosage forms of lipophilic drugs, because 
easy formation at ambient temperature is particularly advantageous for thermo labile 
drugs such as peptides [14]. Phase study revealed that the addition of Cremophor EL-
Transcutol mixture in a ratio 4:1 can produce clear and transparent microemulsions in 
the subsequent study.  
2.2 Solubility of drug in the surfactants and oil 
The solubility of Cyclosporin A in each component was 98.72  7.75 mg/g in Captex 
355(oil), 56.51  4.90 mg/g in Cremophor EL (surfactant) and very soluble in 
Transcutol(cosurfactant). The solubility of Cyclosporin A in the oil-surfactant mixture was 
slightly decreased with increasing the content of Cremophor EL (Fig. 2A). In contrast, the 
solubility of Cyclosporin A in the oil-cosurfactant mixture was increased linearly with 
increasing the content of Transcutol (Fig. 2B). Fig. 2C shows that the solubility of 
Cyclosporin A in the oil-Smix mixture with varying surfactant-cosurfactant ratio was 
decreased with increasing the surfactant content. It indicates that the solubilization of 
Cyclosporin A was greatly affected by the cosurfactant content. After adding the aqueous 
phase, the solubility of Cyclosporin A in oil-surfactant-water system increased linearly with 
increasing the content of Cremophor EL (Fig. 3A). The solubility of Cyclosporin A in oil-
cosurfactant-water system also increased dramatically with more than 0.5% of Transcutol  
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Fig. 2. (A) Effect of the content of Cremophor EL on the solubility of Cyclosporin A in a 
mixture of Cremophor EL and Captex 355. (B) Effect of the content of Transcutol on the 
solubility of Cyclosporin A in a mixture of Transcutol and Captex 355. (C) Effect of the 
weight ratio of Cremophor EL to Transcutol on the solubility of Cyclosporin A in a 
mixture of Cremophor EL-Transcutol (Smix) and Captex 355 (Smix:Captex 355=15:4). 
 
 
            (a)   (b)              (c) 
Fig. 3. (A) Effect of the content of Cremophor EL on the solubility of Cyclosporin A in a 
mixture of Cremophor EL, Captex 355 and saline (Cremophor ELCaptex 355: 
saline=19:81). (B) Effect of the content of Transcutol on the solubility of Cyclosporin A in a 
mixture of Transcutol, Captex 355 and saline (TranscutolCaptex 355:saline=19:81). 
(C) Effect of the weight ratio of Cremophor EL to Transcutol on the solubility of 
Cyclosporin A in microemulsion systems obtained by adding saline to a mixture of 
Cremophor EL-Transcutol (Smix) and Captex 355(Smix:Captex 355=15:4). 
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(Fig. 3B). The solubility of Cyclosporin A in a system containing all of the components for 
producing microemulsions (Fig. 3C) was increased markedly compared to those of 
systems without surfactant (Fig. 3B) or cosurfactant (Fig. 3A) and it reached the maximum 
(21.95  1.48 mg/ml) when the ratio of surfactant to cosurfactant of Smix was 2:1 (Fig. 3C). 
The maximized solubilization is thought to be achieved by the formation of transparent 
microemulsion with small droplets. At the ratios greater than 2:1, although these mixtures 
formed microemulsions, the less Transcutol content in the microemulsion systems was 
caused the solubilizing capacity of microemulsion to be decreased. In contrast, at the ratio 
less than 2:1, the clear microemulsion cannot be produced due to the insufficient amount 
of surfactant. The slight increase of solubility of Cyclosporin A at the ratio of 0.5:1 is 
thought to be observed due to the fact that, although the clear microemulsion cannot be 
formed, the excess amount of cosurfactant existed in the water phase and increased the 
solubility of Cyclosporin A in the aqueous phase. It was also confirmed by determining 
the partitioning of Cyclosporin A between lipophilic and aqueous phases in the 
subsequent study (Fig. 4).  
2.3 Partitioning of Cyclosporin A between lipophilic and aqueous phases (Co/Cw) 
Partitioning studies using the aqueous and oil phases of corresponding microemulsion are 
known to be correlated to the observed oral bioavailability and/or in vitro permeability [11]. 
The concentration ratio of Cyclosporin A in lipophilic phase to that in aqueous phase 
(Co/Cw) was greatly affected by the ratio of surfactant to cosurfactant of Smix (Fig. 4). Co/Cw 
was maximized when the microemulsion system was prepared with Smix at 1:1 ratio of 
surfactant to cosurfactant. When the ratio was at above or below 1:1, the Co/Cw was reduced 
because the excess amount of surfactant or cosurfactant existed in the aqueous phase and 
contributed to increasing the concentration of Cyclosporin A in aqueous phase. However, if 
considering the absolute solubility of Cyclosporin A in the lipophilic phase, the maximized 
concentration of Cyclosporin A could be obtained with microemulsions containing 2:1 
mixture of surfactant to cosurfactant. 
 
Fig. 4. Effect of the weight ratio of Cremophor EL to Transcutol on the concentration ratio 
of Cyclosporin A in lipophilic phase and that in aqueous phase of microemulsion systems 
(Co/Cw). 
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Fig. 5. Disperison rate of mixture of Cremophor/Transcutol(Smix) (Cremophor 
EL®/Transcutol® as 0.5:1, 1:1, 2:1, 3:1, 4:1 and Captex 355 (Smix:Captex355=15:4) into 
aqueous media assuming the pH condition of gastric fluid. 
2.4 Dispersability and particle size determination 
To use the oil-Smix mixture as a pre-microemulsion concentrate, it must be readily dispersed 
in the stomach to form a microemulsion [10]. Thus, the dispersability of oil-Smix mixture 
prepared with different weight ratios of surfactant to cosurfactant was compared in aqueous 
media assuming the pH condition of gastric fluid. The dispersion occurred more slowly 
with increasing the surfactant/cosurfactant ratio (Fig. 5). Too slow dispersion of pre-
microemulsion concentrate prepared with Smix which is greater than 3:1 ratio of surfactant to 
cosurfactant might retard the absorption of drugs in gastrointestinal tract and it was insisted 
that the ratio of surfactant to cosurfactant must not exceed 2:1 to allow use of the oil-Smix 
mixture as a pre-microemulsion concentrate in this study.  
It is known that the droplet size distribution is one of the most important characteristics of 
emulsion for the evaluation of its stability [15] and also in vivo fate of emulsion [16]. At first, 
the effect of each component of microemulsion systems on the resultant droplet size was 
investigated. The surfactant content at below 20% of mixture did not affect the droplet size 
significantly (Fig. 6A). However, with increasing the cosurfactant content in oil-
cosurfactant-water system, the droplet size decreased linearly (Fig. 6B). The droplet size of 
microemulsions prepared with Smix was markedly reduced compared with those prepared 
with surfactant or cosurfactant alone. It was demonstrated that the small and stable 
microemulsion was formed by the addition of both of them. The droplet size of 
microemulsion decreased with increasing of the surfactant to cosurfactant ratio and became 
constant at above 2:1 ratio of surfactant to cosurfactant (Fig. 6C). This result is in accordance 
with the report that the addition of surfactant on the microemulsion systems causes the 
interfacial film to condense and to be stable, while the addition of cosurfactant causes the 
film to expand [14]. The smallest droplet size of microemulsion (22 nm) was obtained from 
Smix at more than 2:1 ratio of surfactant to cosurfactant, where it can produce clear and 
transparent microemulsions. However, as mentioned in the proceeding sections, Smix at 3:1 
or 4:1 ratio of surfactant to cosurfactant produced microemulsions with reduced drug-
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solubility capacity and slow dispersion rate, which can be disadvantageous for use as an 
oral delivery system of Cyclosporin A.  
 
Fig. 6. (A) Effect of the content of Cremophor EL in a mixture of Cremophor EL, Captex 
355, and saline (Cremophor ELCaptex 355:saline=19:81) on the resultant mean droplet 
size. (B) Effect of the content of Transcutol in a mixture of Captex 355, Transcutol and 
saline (TranscutolCaptex 355:saline=19:81) on the resultant mean droplet size. (C) Effect 
of the weight ratio of Cremophor EL and Transcutol in empty microemulsion obtained 
from a mixture of Cremophor-Transcutol (Smix), Captex 355 and saline (Smix:Captex 
355:saline=15:4:81) on the resultant mean droplet size. 
2.5 Animal studies 
The non-compartmental pharmacokinetic parameters in Table 1 were calculated based on 
the observed blood data. The maximal drug concentration in blood( Cmax), time at the 
maximal drug concentration in blood(Tmax) and Area Under Curve of drug concentration in 
blood (AUC) of Sandimmun, Sandimmun Neoral and microemulsion in this study were 
1.285, 2.859, 3.275 (g ml-1) and 2.333, 3.000, 3.667 (h) and 12.531, 33.171, 41.332 (gh/ml), 
respectively. The Cmax of Cyclosporin A loaded in the microemulsion system in the present 
study was markedly higher compared with Sandimmun and was not significantly different 
compared with Sandimmun Neoral. The AUC of Cyclosporin A via oral administration of 
microemulsion in this study was significantly increased (p<0.05, 3.30 fold), when compared 
with Sandimmun. However, no significant difference was found between the AUC of 
microemulsion and Sandimmun Neoral (p>0.05, 1.25 fold). There was no significant 
change in Tmax (p>0.05) among the three products. The absolute bioavailability (F) of 
microemulsion optimized in this study increased about 3.30 and 1.25 fold compared with 
Sandimmun and Sandimmun Neoral. The bioavailability of Cyclosporin A incorporated 
in microemulsion optimized did not show significant difference compared with Sandimmun 
Neoral (0.416 versus 0.518) and 3.30 fold increased compared with Sandimmun (0.157 
versus 0.518). It is thought that this result support the report that for lipophilic drugs and 
peptides, where absorption is dissolution rate limited, a strong correlation exists between 
the particle size of emulsion and bioavailability because the particle size of Sandimmun, 
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Sandimmun Neoral and microemulsion (with Smix 2:1) in this study was 864, 104 nm and 
22 nm, respectively, measured with Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK) 
after diluting with water 50 times.  
Parameters Intravenous 
Oral 
Sandimmun Sandimmun 
Neoral Microemulsion 
Cmax (g ml-1) 
Tmax (h) 
AUC (gh/ml) 
 
Absolute 
bioavailability (F) b 
 
 
390 0.193 
 
 
285 0.088 
333 0.441 
12.531 0.088 
 
0.157 
2.859 0.322 
3.000 0.354 
33.1715.534 a 
 
0.416 
3.275 0.367 a 
3.667 0.333 
41.332 4.532 a 
 
0.518 
a p<0.05 by the student T-test when compared to Sandimmun.  
Table 1. Analysis of noncompartmental pharmacokinetic parameters after oral 
administration of cyclosporin A products to rats. 
2.6 Conclusion 
The surfactant to cosurfactant ratio greatly affected on the physicochemical characteristics of 
resultant microemulsion systems obtained by using polyoxyethylated castor oil (Cremophor 
EL) as a surfactant, Transcutol as a cosurfactant and caprylic/capric triglyceride (Captex 
355) as an oil. The stable microemulsion with high solubility of Cyclosporin A, small 
droplet size and fast dispersion rate was obtained from mixture composed of 10/5/4 
mixture of Cremophor EL/ Transcutol/ Captex 355. The enhancement of bioavailability 
of Cyclosporin A by using o/w microemulsion optimized in this study is thought to be due 
to the combination of factors including the drug solubilization effect and the increase of 
drug permeability to membrane. In other words, the bioavailability of drugs loaded in 
microemulsions was dependent on the physicochemical properties of drug and o/w 
microemulsions. This system might be applicable to formulate the liquid and solid dosage 
forms of Cyclosporin A for enhancing its bioavailability after oral administration. This 
formulation approach can also help to improve the oral bioavailability of other poorly 
soluble peptide drugs as is the case for Cyclosporin A.  
3. Emulsion for hydrophobic drug oral delivery 
Biphenyl dimethyl dicarboxylate (BDD) is an agent against virally induced hepatic injury 
and has been found to be effective in improving liver function and symptoms of patients 
with chronic viral hepatitis [17, 18, 19]. BDD is practically water-insoluble (3.6 μg/ml in 
water at 25°C) and its dissolution rate is extremely slow, resulting in very low 
bioavailability (20–30%) [20]. For enhancement of the solubility and bioavailability of BDD 
after oral administration, an Emulsion system composed of oil (Neobee M-5®), surfactant 
(Tween 80), and cosurfactant (Triacetin), was prepared, and its physicochemical properties 
and pharmacokinetic parameters were evaluated in comparison to commercial product G-
cell and 0.5% calcium-carboxymethylcellulose (Ca-CMC) suspension of BDD. 
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3.1 Solubility of BDD in various ratios of surfactant to oil 
The solubility of BDD sharply increased from 0.7 to 5.02 mg/g as the ratio of Tween 80 to 
Neobee M-5® increased from 1:4 to 2:1 and leveled off above the ratio of 2:1 (Fig. 7). At the 
ratio of 2:1, the solubility of BDD increased 7-fold compared with that at the ratio of 1:4. 
Hence, the ratio of 2:1 (Tween 80 to Neobee M-5®) was used for further studies.  
 
Fig. 7. Solubility of BDD in various ratios of Tween 80 to Neobee M-5®. Each point 
represents the mean  SD of three experiments. 
3.2 Solubility of BDD in an Emulsion system containing Triacetin 
Triacetin has been used as oil to solubilize water-insoluble taxol [21] and as a food additive 
because of its good solubility in water and potential role as a parenteral nutrient [22]. In this 
study, the solubility of BDD in the absence of Tween 80 and Neobee M-5® increased 
proportionately with the added amount of Triacetin ranging from 0 to 50% (Fig. 8) Thus, to  
 
Fig. 8. Effect of Triacetin on the solubility of BDD. Each point represents the mean of four 
experiments.  
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further enhance the solubility of BDD, Triacetin was employed in a emulsion system 
composed of Tween 80 and Neobee M-5® at the ratio of 2:1. When the Triacetin was added 
to a emulsion system composed of Tween 80 and Neobee M-5® at the ratio of 2:1, the 
solubility of BDD gradually increased. With 55% of Triacetin, the solubility of BDD 
increased 40% compared to that without Triacetin, indicating the role of Triacetin as a 
cosurfactant in a emulsion system. Moreover, the presence of Triacetin in the emulsion 
system composed of Tween 80 and Neobee M-5® at the ratio of 2:1 led to the decrease in 
droplet size with higher physical stability and the increase in dissolution rate of BDD in 
aqueous media (data not shown). For further studies, 35% of Triacetin that led to 20% 
increase in solubility of BDD was chosen since the amount of Triacetin allowed for oral 
administration is less than 35%. 
3.3 Droplet size of a microemulsion system 
Droplet size of BDD emulsion composed of Tween 80 and Neobee M-5® at the ratio of 2:1, 
and 35% of Triacetin was kept constant both in distilled water and artificial gastric fluid 
without pepsin (pH 1.2) throughout 120 min incubation period The droplet sizes at 1 h after 
incubation in distilled water and artificial gastric fluid were 329.97  24.31 and 284.07  44.39 
nm, respectively, without further changes at 2 h. This result suggests that the microemulsion 
system may be stable and well-dispersed in the GI tract. 
3.4 Comparison of dissolution profiles among different formulations of BDD 
The dissolution profiles of BDD powder, 0.5% Ca-CMC suspension of BDD, Commercial 
formulation G-cell and the emulsion formulation (SEDDS) of BDD composed of Tween 80 
and Neobee M-5® at the ratio of 2:1, and 35% of Triacetin in distilled water were compared 
(Fig. 9). BDD in the emulsion formulation rapidly dissolved to a great extent whereas BDD 
in other formulations did hardly dissolve during 120 min incubation. About 50% of BDD in 
the emulsion formulation dissolved within 10 min.  
 
Fig. 9. Dissolution profiles of BDD from 0.5% Ca-CMC suspension of BDD, BDD powder, 
and the emulsion formulation of BDD (Tween 80 and Neobee M-5® at the ratio of 2:1, and 
35% Triacetin; SEDDS).  
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Fig. 10. Plasma concentration of BDD after oral administration to rats of 0.5% Ca-CMC 
suspension of BDD, BDD solution formulation and the emulsion formulation of BDD 
(Tween 80 and Neobee M-5® at the ratio of 2:1, and 35% Triacetin) at a dose equivalent to 12 
mg of BDD/kg of body weight. Each point represents the mean  SD of seven rats. 
3.5 Pharmacokinetic analysis 
An in vivo absorption study was undertaken to determine whether or not the enhanced 
solubilization and in vitro dissolution of BDD in a emulsion system could increase the GI 
absorption of drug after oral administration. Plasma concentration of BDD after oral 
administration of BDD in the emulsion formulation to rats increased rapidly and 
remarkably compared with 0.5% Ca-CMC suspension of BDD and BDD solution 
formulation (Fig. 10). AUC0→24h of BDD in the emulsion formulation increased 5.0-fold and 
1-fold compared with that of BDD in 0.5% Ca-CMC suspension and BDD solution 
formulation (9.829 vs. 1.955 g·h/ml and 1.718 vs. 1.955 g·h/ml) (Table 2). The emulsion 
formulation of BDD also enhanced Cmax of BDD by 9.8-fold and 1.1-fold compared with  
Parameters Emulsion formulation 
BDD in 0.5% Ca-
CMC suspension 
BDD solution 
formulation 
Cmax (g/ml) 1.550 ±0.706** 0.158 ±0.165 0.1412 ±0.602 
Tmax (h) 1.833 ±1.125 1.254 ±1.025 1.788 ±2.777 
AUC (gh/ml) 9.829 ±2.255** 1.955 ±0.712 1.718 ±0.536 
** p < 0.01 when compared with 0.5% Ca-CMC suspension and BDD solution formulation by the 
ANOVA test. 
Table 2. Noncompartmental pharmacokinetic parameters after oral administration of BDD 
products to rats. 
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0.5% Ca-CMC suspension of BDD and BDD solution formulation (1.550 vs. 0.158 g/ml 
and 0.1412 vs. 0.158 g/ml) (Table 2). However, Tmax was not significantly different 
between two formulations (Table 2). These results indicate that the emulsion system of 
BDD considerably increases the bioavailability of BDD compared with 0.5% Ca-CMC 
suspension of BDD and BDD solution formulation. The enhanced bioavailability is 
probably due to the increase in solubility and dispersion of the drug in the GI tract. 
Nerurkar reported that surfactants, which are commonly added to pharmaceutical 
formulations, might enhance the intestinal absorption of some drugs by inhibiting this 
apically polarized efflux system [23]. In this study, the presence of a surfactant, Tween 80, 
in the emulsion system might have caused changes in membrane permeability, which 
could lead to an increase in bioavailability of the drug. It is thus expected that the 
increased bioavailability of BDD from a emulsion system may result in improved efficacy, 
allowing patients to be able to take less BDD.  
3.6 Conclusions 
Taken together, these results demonstrate that the microemulsion formulation of BDD 
composed of Tween 80 and Neobee M-5® at the ratio of 2:1, and 35% of Triacetin 
considerably improves the bioavailability of a poorly water-soluble BDD after oral 
administration, possibly due to the increase in solubility and dispersion of the drug in the 
GI tract. Therefore, the emulsion system may provide a useful dosage form for oral intake of 
water-insoluble drugs such as BDD. 
4. Thermal revisable microemulsion for oral delivery of poorly water-soluble 
drugs  
To avoid the precipitation of poorly water soluble drug in the pre-microemulsion, we 
prepared a solid or semi-solid dosage form and it would change into liquid state at body 
temperature. Poorly water soluble drug YH439 was loaded in a thermal reversible 
microemulsion system which can disperse rapidly in the aqueous contents of the stomach 
and form fine oil in water droplets, and thus leads to improve absorption of the poorly 
water soluble drugs as indication in Figure 11. 
 
Fig. 11. Thermo sensitive SEDDS (Self-Emulsified Drug delivery System) 
4.1 Effect of the composition ratio on melting point and particle size 
The melting point of mixture of Pa-PEG (Palmitic-PEG400) and Ca-PEG( Capric-PEG400) 
was increased with increasing the composition ratio of Ca-PEG to Pa-PEG as shown in 
Figure 12. At the ratio of Ca-PEG to Pa-PEG was 1:3, the melting point was close to the body 
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temperature as 36ºC. Thus, firstly, the ratio of Ca-PEG to Pa-PEG was fixed at 1:3, then the 
effect of Cremorphor RH40® as a surfactant and Neobee M-5® as an oil on melting point of 
thermal reversible microemulsions was examined and the optimal composition ratio was 
determined for the thermal reversible microemulsion system. The melting point of thermal 
reversible microemulsions was raised up with increasing the amount of oil in the 
formulation as shown in Figure 13(a). Whereas, the melting point of microemulsions 
decreased with increasing the amount of surfactant. When the microemulsion was 
composed of lipid matrix, surfactant and oil with a ratio of 5:4:1, its melting point was close 
to the body temperature as 37ºC. Thus this would be considered as the pre-concentration of 
microemulsion since the solid state could change to liquid state around 37ºC and rapidly 
form fine droplets microemulsion in gastrointestinal tract. 
Effect of each component of microemulsion systems on the resultant droplet size was 
investigated as shown in Figure 13(b). In the range of surfactant with more than 0.2 g and 
oil with less than 0.2 g, small droplet size (< 100nm) of microemulsion was obtained in 
this system. The droplet size of microemulsion was significantly reduced with increasing 
the amount of surfactant. At the composition ratio of lipid matrices:Cremorphor 
RH40®:Neobee M-5® with 5:4:1, the smallest droplet with 28 nm of mean size was 
obtained. The smaller sizes of droplets will have a larger interfacial surface areas per unit 
volume and correspondingly large free energy contribution from the liquid-liquid 
interfacial tension. As reducing the size of droplets, a larger interfacial surface areas per 
unit volume could be produced. 
Thus from the results, the optimal physical properties including melting point and particle 
size of microemulsion were produced by the composition ratio of lipid 
matrices:Cremorphor RH40®:Neobee M-5® with 5:4:1. This formulation would be used as a 
formulation of the thermal reversible microemulsion system for further study in the work. 
Percentage of Ca-PEG to Pa-PEG
020406080100
M
el
tin
g 
Po
in
t (
o
C)
0
20
40
60
 
Fig. 12. The change of melting point was function of altering the composition ratio of Capric-
PEG400 to Palmitic-PEG400. 
www.intechopen.com
 Thermal Reversible Microemulsion for Oral Delivery of Poorly Water-Soluble Drugs  
 
147 
 
          (a)        (b) 
Fig. 13. Effect of oil and surfactant on changing melting point (a) and particle size (b) of 
microemulsion system. The ratio of Capric-PEG400 to Palmitic-PEG400 was fixed at 1:3 and 
the lipid mixture of Capric-PEG400 and Palmitic-PEG400 was equivalent to 1 g. 
4.2 Release profile of YH439 from thermal reversible microemulsion  
The YH439 was released from various formulations including powder form, 5% of Ca-CMC 
suspension, Gelucire® and the thermal reversible microemulsion prepared in this work. The 
powder form of YH439 was released less than 5% of initial amount and after suspending in the 
5% of Ca-CMC, the YH439 was released upto 20%. However, by additions of the Gelucire® 
formulation and the microemulsion to YHP439, 90% of YHP439 was released until 180 min as 
shown in Figure 14. The systems of Gelucire® and microemulsion remarkably improved the  
Time (min)
0 30 60 90 120 150 180
Am
o
u
n
t o
f Y
H
43
9 
re
le
a
s
e
d 
(%
)
0
20
40
60
80
100
Microemulsion
Gelucire formulation
5% Ca-CMC suspension
YH439 powder
 
Fig. 14. Release profiles of YH439 from the thermal reversible microemulsion, Glucire® 
formulation, 5% Ca-CMC suspension and powder state of YH439. The thermal reversible 
microemulsion was composed of lipid matrices, Cremorphor RH40® and Neobee M-5® with 
a ratio of 5:4:1. 
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release property compared with powder form and 5% of Ca-CMC suspension. On the other 
hand, the fast release pattern was observed in the microsemulsion system compared with the 
Gelucire® formulation. This is desirable property since a slow dissolution rate of formulation 
might retard the absorption of drugs in the gastrointestinal tract.  
4.3 The transport of YH439 across the caco-2 cell monolayer 
The apparent permeability (Papp) of YH439 from the apical to the basolateral and 
basolateral to apical were calculated according the equation mentioned above. Papp of 
YH439 from the apical to the basolateral and basolateral to apparent direction were 2.0810-5 
cm/s, 4.7110-5 cm/s for 0.63 uM, YH439. It was suggested YH439 was transported in the 
basolateral to apical direction is larger than from apical to basolateral direction in the 
present of a transport system as shown in Figure 4. It has been reported that the efflux of 
YH439 which is found in Caco-2 cells does not appear to influence the bioavailability of 
YH439 (Evidenced by the sufficiently high permeability in the absorption direction)14. 
YH439 was transported from microemulsion formulation larger than Gelucire® formulation 
and 5% Ca-CMC suspension as shown in Figure 15. The results were expected to response 
to in vivo animal experiments. 
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Fig. 15. Effect of YH439 transport from apical to basolateral and basolateral to apical in the 
microemulsion formulation, Glucire® formulation, and 5% Ca-CMC suspension (n=4).  
4.4 Pharmacokinetic analysis  
In vivo study was undertaken to examine the effect of a thermal reversible microemulsion 
system of YH439 on G.I. absorption after oral administration equivalent to 15 mg/kg of 
YH439 to rats. The plasma concentration of YH439 after oral administration of YH439 in the 
thermal reversible microemulsion formulation to rats increased compared with in the 
Gelucire® formulation and 5% Ca-CMC suspension as shown in Figure 5. AUC0-24 of YH439 
in the thermal reversible microemulsion formulation increased 1.17-fold and 6.91-fold 
compared with that of Gelucire® formulation and 5% Ca-CMC suspension (28.14 vs 24.01 
µg·h/ml and 28.14 vs 4.07 µg·h/ml) as listed in Table 2. The thermal reversible 
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microemulsion formulation of YH439 also enhanced Cmax of YH439 by 1.59-fold and 7.29-
fold compared with Gelucire® formulation and 5% Ca-CMC suspension (2.26 vs 1.42 µg/ml 
and 2.26 vs 0.31) (Table 2). However, the significant difference was not observed in Tmax 
value (Table 3). These results indicated that the thermal reversible microemulsion 
formulation of YH439 considerably increased the bioavailability of YH439 compared with 
Gelucire formulation and 5% Ca-CMC suspension. The enhanced bioavailability was very 
probably due to the increasing drug dispersion in the GI tract. Therefore, the increased 
solubility and enhanced bioavailability of YH439 from a thermal reversible microemulsion 
could result in improved drug efficacy. 
Parameters Intravenous 
Oral 
Microemulsion Gelucire® Suspension 
Cmax (mg/ml) - 2.26±0.47a,b 1.42±0.10 a 0.31±0.85 
Tmax (min) - 30 30 30 
AUC (mg·h/ml) 6.11±0.28 28.14±2.89a 24.01±2.78 a 4.07±032 
Absolute 
Bioavailability (F%)c 
- 76.75 a,b 65.49 a 11.10 
aP<0.001 by the AVOVA when compared to suspension 
bP<0.05 by the AVOVA when compared to suspension 
cF=[AUCoral/Doseoral]/[AUCi.v/Dosei.v] 
Table 3. Plasma concentration of YH439 after oral administration of thermal reversible 
microemulsion, Glucire® formulation and 5% Ca-CMC suspension to rats at the dose of 15 
mg/kg and after intravenous administration of thermal reversible microemulsion 
equivalent to 2.5 mg/kg as YH439 to rats (each group n=6). 
4.5 Conclusion 
The thermal reversible microemulsion system of YH439 was prepared from a lipid mixture 
of Ca-PEG and Pa-PEG, Cremophor RH40® and Neobee M-5® at the ratio of 5:4:1. The 
thermal reversible microemulsion promoted to increase the solubility of a poorly water-
soluble YH439 and to enhance its bioavailability after orally administration to rat. The 
increased stability of poorly water-soluble YH439 by thermal reversible microemulsion 
system could lead to rapidly disperse as fine droplets inclusion drug in the gastrointestinal 
tract. Therefore, the thermal reversible microemulsion system could provide a useful dosage 
form for oral intake of water-insoluble YH439. 
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